These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 16728921)

  • 1. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted agents for adjuvant therapy of colon cancer.
    Saif MW
    Clin Colorectal Cancer; 2006 May; 6(1):46-51. PubMed ID: 16796791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab in the treatment of colorectal cancer.
    Ciardiello F; De Vita F; Orditura M; Comunale D; Galizia G
    Future Oncol; 2005 Apr; 1(2):173-81. PubMed ID: 16555987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
    Cercek A; Saltz LB
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
    Chong G; Cunningham D
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S55-8. PubMed ID: 16399433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of targeted therapy in the treatment of colorectal cancer.
    Goldberg RM; Hurwitz HI; Fuchs CS
    Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
    Franson PJ; Lapka DV
    Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
    Galizia G; Lieto E; De Vita F; Orditura M; Castellano P; Troiani T; Imperatore V; Ciardiello F
    Oncogene; 2007 May; 26(25):3654-60. PubMed ID: 17530019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First- and second-line therapy of metastatic colorectal cancer.
    Terstriep S; Grothey A
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):921-30. PubMed ID: 16761936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current issues in the targeted therapy of advanced colorectal cancer.
    Knijn N; Tol J; Punt CJ
    Discov Med; 2010 Apr; 9(47):328-36. PubMed ID: 20423677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future development of bevacizumab in colorectal cancer.
    Díaz-Rubio E; Schmoll HJ
    Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenesis agents in colorectal cancer.
    Hubbard J; Grothey A
    Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
    Nygren P; Sørbye H; Osterlund P; Pfeiffer P
    Acta Oncol; 2005; 44(3):203-17. PubMed ID: 16076691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
    Mahtani RL; Macdonald JS
    Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.